Abstract: What is disclosed is a method for creating a database for determining a virtual reference value for a light transmission aggregometry measurement, comprising the following steps: a. providing platelet-rich plasma “PRP” (17) of a reference blood sample; b. performing a light transmission measurement with a first light wavelength and a second light wavelength (14), different from the first, on the PRP (17) of the reference blood sample; c. providing platelet-poor plasma “PPP” of the reference blood sample; d. performing a light transmission measurement on the PPP in order to determine a PPP reference value; e. assigning the measurement result of step d to the measurement results of step b in a database; f. repeating steps a to e for a plurality of reference blood samples. The database obtained using this method makes it possible to determine a virtual reference value that is an excellent estimate of the PPP reference value.

Abstract: Systems and methods for conducting surface-mediated chemical and/or biochemical reactions within an enclosed chamber are disclosed. Systems and methods of the present disclosure may be used in conducting hybridization reactions of biopolymers. In some examples, an improved method for mixing thin films of solutions in a hybridization chamber includes altering the direction of mixing at least once over the course of a reaction. In some examples, an improved method for mixing thin films of solutions in a hybridization chamber includes altering the speed of mixing at least once over the course of a reaction. In some examples, an improved method for mixing thin films of solutions in a hybridization chamber includes altering the speed of mixing and the direction of mixing at least once over the course of a reaction.

Abstract: Provided is a platelet aggregation capacity analyzer including a blood coagulation system-analyzing unit that analyzes a platelet aggregation capacity based on measurement data during a coagulation process of a platelet-containing sample, and an output control unit that controls an output of results analyzed by the blood coagulation system-analyzing unit, in which the blood coagulation system-analyzing unit analyzes the platelet aggregation capacity of the platelet-containing sample based on the barb of measurement data during the coagulation process with a platelet aggregation inhibitor added to the platelet-containing sample and measurement data during the coagulation process without a platelet agonist or the platelet aggregation inhibitor added to the platelet-containing sample.

Abstract: The present disclosure relates to, at least, a vacuum-assisted method for infiltrating cadaver bone with a cryoprotectant and a method for rapidly warming the cryopreserved cadaver bone for bone marrow processing.

Abstract: A measurement method of simply and quickly measuring platelet aggregation, is provided. The measurement method is a platelet aggregation analysis method, including: a step of adding a platelet-inducing substance and a calcium salt to a platelet-containing specimen; a step of stirring the platelet-containing specimen; and a step of acquiring measurement data of an electrical characteristic and/or viscoelasticity of the platelet-containing specimen.

Abstract: Provided are specific cell-fractionating and -capturing methods which can fractionate and capture, respectively, specific cells (e.g., many types of cancer cells, including cancer cells not expressing EpCAM, or peripheral blood stem cells). Included is a method for fractionating specific cells present in blood or biological fluid, the method including fractionating the blood or biological fluid by centrifugation to collect the specific cells in the blood or biological fluid, the centrifugation being carried out using a container having a low protein adsorbing layer at least partially formed on the inner surface thereof.

Abstract: Provided herein are devices, systems, and methods for analyzing platelet function. In particular, provided herein are simple, portable, accurate and inexpensive small footprint platelet aggregometry devices, systems, and methods.

Abstract: What is described is a kit for preparing a liquid thromboplastin reagent for a prothrombin time assay. The kit simplifies and minimizes reagent preparation time and is stable for 2-5 years.

Abstract: The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.

Abstract: A cuvette comprising: a main body having a sample chamber formed therein, the sample chamber communicating with the exterior of the cuvette by an opening formed in the exterior of the main body, wherein the sample chamber comprises a first sample chamber and a second sample chamber, the first sample chamber being in fluid communication with the opening, and the second sample chamber having a first end which is in fluid communication with the first sample chamber, and a second, closed end, the second sample chamber being in fluid communication with the exterior of the cuvette only through the first chamber, the first chamber having a width which is greater than that of the second chamber, and further wherein the greatest width of the opening is greater than or equal to the greatest width of the first sample chamber, the greatest width of the first sample chamber is greater than or equal to the greatest width of the second sample chamber, and the width of the sample chamber, passing from the opening to the clos

Abstract: The present invention relates to the use of absorbent particles to improve the detection of a signal corresponding to the presence of an analyte in an analysis method on spot(s), in particular when the signal detection takes place in the presence of a liquid phase. The present invention also relates to an analysis method on spot(s) making it possible to improve the detection of a signal corresponding to the presence of an analyte, in the presence of a liquid phase comprising absorbent particles.

Abstract: A device for monitoring the spatial and temporal dynamics of thrombin that includes a temperature-controlled sealed chamber with a transparent window and a light trap, the chamber being filled with a fluid medium and designed to accommodate a cuvette containing a test sample of blood plasma, and a coagulation activating insert placed into the cuvette, at least one illumination source and at least one first irradiation source and at least one second irradiation source capable of exciting a fluorescence signal of a special marker that forms in the sample during cleavage of a fluorogenic substrate, a camera, a pressure adjustment element capable of maintaining a pressure inside the chamber, the at least one first irradiation source provides irradiation of the sample in a direction perpendicular to the cuvette, and the at least one second irradiation source provides irradiation of the sample at an angle to the cuvette.

Abstract: The present invention is directed to compounds, methods for stabilizing thrombin activity with a thrombin binding oligonucleotide and to stabilized thrombin. The thrombin binding oligonucleotide is capable of inhibiting thrombin activity whereby the inhibition can be reversed with an antisense oligonucleotide.

Abstract: A method of detecting a clot in a measurement chamber of a liquid sample analyzer, the liquid sample analyzer comprising one or more analyte sensors, each one of the one or more analyte sensors being arranged for measuring a physical parameter for a respective analyte in a liquid sample in the measurement chamber, wherein detection is performed after conclusion of a rinsing procedure with a primary solution (Cal2) having a pre-determined primary composition with a primary level of the analyte, the method comprising the steps of: (a) at least partly filling the measurement chamber with a secondary solution (Rinse/Cal1) having a pre-determined secondary composition with a respective secondary level for each of the analytes, wherein the respective secondary level is different from the respective primary level; (b) immediately after filling the measurement chamber with the secondary solution (Rinse/Cal1), obtaining an initial measurement result by each of the one or more analyte sensors; (c) flushing the measurem

Abstract: In some embodiments, the invention provides an in vitro method for identifying a patient as likely as likely to require a transfusion of at least six units of blood in six hours or less. The method comprise, consists essentially of, or consists of (a) analyzing a sample of blood from a patient with a viscoelastic analysis assay to obtain a coagulation characteristic value that is independent of time of the patient; and (b) comparing the coagulation characteristic value of the patient to a coagulation characteristic value that is independent of time of a control, wherein the coagulation characteristic value of the patient that is lower than the coagulation characteristic value of the control identifies the patient as likely to require a transfusion of at least six units of blood in six hours or less.

Abstract: Compositions and methods useful for point of care testing for hemophilia by measuring coagulation factor levels are provided.

Abstract: Examples described herein include detection devices and systems which may provide monitoring in accordance with an analysis mode which may be selected in accordance with a severity of disease of the user. Analysis modes used by detection devices described herein may further be changed in accordance with user and/or environmental conditions.

Abstract: The invention relates to a method of detecting a clot in a measurement chamber of a liquid sample analyzer, wherein the liquid sample analyzer comprises at least two analyte sensors, a first analyte sensor, for measuring a first analyte in a liquid sample, and one or more second analyte sensors, for measuring one or more second analytes in the liquid sample in the measurement chamber, the method comprising the steps of, (a) at least partly filling the measurement chamber with a known solution having a composition comprising the first analyte at a pre-determined level, and the second one or more analytes at pre-determined levels, (b) obtaining a first sequence of measurement results by the first analyte sensor, and simultaneously obtaining a second sequence of measurement results by the second, one or more analyte sensors, (c) determining a change of the first sequence of measurement results, (d) determining a change of the second one or more sequence of measurement results, (e) comparing the change of the fir

Abstract: The present invention relates to device (10) for determining a fibrinogen level (20) in a sample (22) comprising, a first input for obtaining an attenuance signal (24) over time indicative of a fibrin polymerization of said sample (22), a second input for obtaining a reactant concentration signal (28) over time indicative of a reactant concentration in said sample (22), wherein the reactant is any substance leading to the cleavage of fibrinogen to fibrin, a simulation unit (16) running a model (32) using the reactant concentration signal (28) as an input to provide a simulated attenuance signal (34) over time, and an evaluation unit (18) configured to infer the fibrinogen level (20) of said sample (22) by comparing the attenuance signal (24) over time with the simulated attenuance signal (34) over time.

Abstract: A blood analyzing method includes optically measuring a first calibration sample prepared from a fibrin/fibrinogen degradation product (FDP) measurement reagent and a first calibrator containing D-dimer (DD) and having a first value relating to the ratio of the content of FDP to the content of DD, acquiring first calculation data based on temporal change of optical information of the first calibration measurement sample, performing optical measurement of a second calibration measurement sample prepared from FDP measurement reagent and a second calibrator containing DD and having a second value that is different from the first value, acquiring second calculated data based on a temporal change in optical information of the second calibration measurement sample, and acquiring calibration curve information indicating the relationship between the calculation data and the value relating to the amount of DD.

Abstract: Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.

Abstract: A device for collecting a biological sample from a semi-solid surface. The device has a shaft with a proximate end and a distal end and a tip integrated with the shaft at the proximate end. The tip has a surface adapted to collect microorganisms thereon or release microorganism from, or both, wherein the adapted surface comprises at least one feature of a recess or extension to increase surface area of the tip and collect microorganisms thereon. Examples of such features include microfeatures with dimensions of about 1000 ?m or less. Other examples include a pipette tip.

Abstract: Provided herein are methods for generating an estimated coagulation test result from an underfilled sample tube.

Abstract: The present invention provides methods for measuring the absolute concentration of Tau, and other protein, peptide fragments and proteoforms in CSF and plasma samples collected from a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the CSF or plasma concentration of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.

Abstract: Test strips for determining the activity of a coagulation factor in a blood sample are provided. The strip comprises a support, a sample inlet port for deposition of a blood sample, and a reaction area comprising a blood coagulation reagent. The sample inlet port is connected to the reaction area, and the coagulation reagent comprises blood plasma deficient in the coagulation factor for which activity is to be measured, an ionic citrate source an ionic calcium source, and either one or more coagulation contact phase activator reagents and phospholipids or a mixture of tissue factor and phospholipids. The disclosure further relates to in vitro methods for measuring an activity of a coagulation factor.

Abstract: In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention includes methods for classifying an anticoagulant as an anti-Factor Xa or a direct thrombin inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.

Abstract: There is provided a sensor and the like which can detect a first substance with high accuracy. A sensor for detecting whether an analyte contains a first substance, includes a base and a detection section including a second substance immobilized on a surface of the base. The second substance includes an amino acid, a bond which can be cleaved by a reaction with an enzyme, and a first compound which is bonded to the amino acid by the bond and includes a first group capable of bonding to other substances, and the analyte is configured to be introduced to the detection section by being contacted with a third substance which generates the enzyme by a reaction with the first substance.

Abstract: Disclosed is a method for measuring a clotting time, including the steps of: (A) mixing a blood sample, an activator, a phospholipid, and a nickel ion-forming compound to obtain a specimen; and (B) mixing the specimen obtained in step (A) with a calcium salt to prepare a measurement specimen and measuring the clotting time of the measurement specimen.

Abstract: The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.

Abstract: What is described is a kit for preparing a liquid thromboplastin reagent for a prothrombin time assay. The kit simplifies and minimizes reagent preparation time and is stable for 2-5 years.

Abstract: Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.

Abstract: A determination method of a blood sample may include: measuring, with a first coagulation time measurement reagent and a second coagulation time measurement reagent which contain phospholipids at different concentrations, coagulation times of a blood sample of a subject, coagulation times of a normal blood sample, and coagulation times of a mixed sample including the blood sample of the subject and the normal blood sample; acquiring a first index value and a second index value based on the coagulation times; and determining whether the blood sample of the subject is a blood sample containing a direct anticoagulant based on the first index value and the second index value.

Abstract: Embodiments of a platelet testing system include an analyzer console device and a blood testing cartridge configured to releasably install into the console device. The cartridge device is configured with one or more measuring chambers and one or more mixing chambers that are fluidically connected within the cartridge device that enable the mixing of saline and a blood sample to a desired dilution. Additionally, the cartridge device is further configured with a cartridge slider that provides a reagent bead to the saline and blood mixture at a desired time. As such, one or more platelet activation assays can be conducted by measuring, through cartridge electrodes of the cartridge device, the detectable changes in platelet activity within the blood and saline mixture.

Abstract: The present invention relates to improved clotting compositions for producing high quality blood serum samples for analyte testing, such as for pathology testing and other biological assays. In particular, the present invention relates to the use of prothrombin activators in combination with stabilizing agents such as colloids for producing high quality blood serum samples. The present invention also relates to associated methods for preparing clotting compositions, tubes, kits and methods of diagnosis, prognosis and monitoring for responsiveness to therapy.

Abstract: Hand-held optical thromboelastographic sensor and method of using the same for simultaneous assessment of multiple parameters of blood coagulation at a point-of-care. The sensor includes an optical system registering laser speckle intensities associated with portions of a blood sample delivered through a fluid switch to analysis chambers of a cartridge of the sensor, and data-processing circuitry programmed to derive the multiple parameters from speckle intensity. The circuitry may be part of a mobile device configured to operate without communication with a central server and/or data storage.

Abstract: The invention provides assay methods of detecting plasma protease CI inhibitor (Cl-INH) that binds plasma kallikrein, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.

Abstract: The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing endotoxi-induced clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the level of endotoxin present in the sample.

Abstract: The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.

Abstract: The present invention relates to a method for acquiring information on a cause of prolongation of coagulation time. The present invention also relates to a device, a system and a computer program for analyzing blood coagulation.

Abstract: Methods are described for quantifying an amount of natural rubber in a plant from a sample of the plant by obtaining a T1 spin-lattice relaxation rate or T2 spin-spin relaxation rate from a NMR apparatus, such as a low-field NMR apparatus operating at a magnetic field strength of 2 T or less. The NMR relaxation rates obtained from the plant sample are compared to reference relaxation data or plots. The plots can represent the weight percent polyisoprene versus T1 spin-lattice relaxation rate or T2 spin-spin relaxation rate. The reference relaxation data or plots are generated from testing the same type of plant as the sample.

Abstract: The present invention relates to a method for in vitro determining generation of a haemostasis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.

Abstract: Methods and systems for releasing growth factors are disclosed. In certain embodiments, a blood sample is exposed to a sequence of one or more electric pulses to trigger release of a growth factor in the sample. In certain embodiments, the growth factor release is not accompanied by clotting within the blood sample.

Abstract: The present invention concerns diagnostic methods for coagulation testing involving determining anticoagulant activity elicited by a first anticoagulant in a sample comprising measuring a first Factor Xa activity in a body fluid test sample of said subject, measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, calculating an universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities and comparing the said parameter for the anticoagulation activity with predefined ranges of expected anticoagulation activity for at least three anticoagulants. Further provided is a computer program code assisting the method as well as a system for carrying out the said method as well as a kit.

Abstract: A substrate for use in a filter media including, for example, in a hydrocarbon fluid-water separation filter; methods of identifying the substrate; methods of making the substrate; methods of using the substrate; and methods of improving the roll off angle of the substrate. In some embodiments, the substrate includes a hydrophilic group-containing polymer or a hydrophilic group-containing polymer coating.

Abstract: A signal reference value (SLocal) is set at which a blood coagulation reaction time (T) of a blood coagulation time reference sample measured on the basis of the result of comparing a signal value (amount of transmitted light, amount of scattered light, amount of fluorescence, or turbidity) pertaining to blood coagulation time that varies temporally according to the mixing and reaction of the blood coagulation time reference sample and a reagent and a signal reference value (S) corresponds to an expected value (Te) for the blood coagulation reaction time that has been set beforehand so as to correspond to the blood coagulation time reference sample. As a result, it is possible to use the blood coagulation time reference sample to determine the state of the reagent and enhance the reliability of measurement results by setting a unique signal reference value for each reagent container.

Abstract: Methods and kits for the diagnosis of primary hyperaldosteronism (PHA). In particular, the present invention relates to the use of a new diagnostic parameter that is composed of the ratio between the Ang II level, in particular the steady state equilibrium Ang II level, and the aldosterone level in a biological sample, such as e.g. plasma. The ratio of the two measured parameters is used to diagnose PHA in patients and has clear advantages over currently used diagnostic methods.

Abstract: It is an object of the present invention to provide a measurement method capable of easily evaluating combined effects in a single assay system, when antithrombotic agents having different mechanisms of action are used in combination. A method for measuring thrombin generation comprising: (1) a step of adding an anticoagulant, a P2Y12 receptor inhibitor, adenosine diphosphate and tissue factor to platelet rich plasma; (2) a step of adding a fluorogenic thrombin substrate and a calcium-containing solution thereto; and (3) a step of measuring fluorescence intensity.

Abstract: Disclosed are methods and systems for measuring serotonin in a sample using liquid chromatography and mass spectrometry.

Abstract: Featured is a method for assessing risk of a patient condition. Such a method includes providing criteria that relate predetermined parameters to each other, inputting observations into given criterion and relating observations of one or more acquired parameters, and converging the given criterion so as to provide an output representative of a patient condition. Such a method further includes translating the output into a visual form such as displaying the output on a display device.

Abstract: A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibrin clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient.